The purpose of this study is to assess the safety and immunogenicity of amezosvatein (CRV-101), an investigational vaccine compared to Shingrix® for the prevention of herpes zoster in adults aged 50 years and older
The purpose of this study is to assess the safety and immunogenicity of amezosvatein (CRV-101), an investigational vaccine compared to Shingrix® for the prevention of herpes zoster in adults aged 50 years and older
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
-
Curevo Investigational Site, Tempe, Arizona, United States, 85281
Curevo Investigational Site, Coral Gables, Florida, United States, 33134
Curevo Investigational Site, Oak Brook, Illinois, United States, 60523
Curevo Investigational Site, Lenexa, Kansas, United States, 66219
Curevo Investigational Site, Newton, Kansas, United States, 67114
Curevo Investigational Site, Lexington, Kentucky, United States, 40509
Curevo Investigational Site, Las Vegas, Nevada, United States, 89119
Curevo Investigational Site, Edmond, Oklahoma, United States, 73013
Curevo Investigational Site, Knoxville, Tennessee, United States, 37909
Curevo Investigational Site, Austin, Texas, United States, 78745
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
50 Years to
ALL
Yes
Curevo Inc,
Lisa Shelton, ARNP, STUDY_DIRECTOR, Curevo Inc
Guy De La Rosa, MD, STUDY_DIRECTOR, Curevo Inc
2032-03-06